News
Video
Author(s):
A more focused discussion on the specific challenges physicians or patients may face when seeking coverage or reimbursement for GnRH agonists/antagonists in prostate cancer.
Healthy diet may lower risk of grade reclassification in patients with GG1 prostate cancer
Dr. Murphy on increasing diversity in cancer clinical trials
PACE-B trial: Five-fraction SBRT noninferior to conventional radiotherapy in prostate cancer
Dr. Schwen on focal therapies for prostate cancer
Lisa F. Newcomb, PhD, on active surveillance for prostate cancer
Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer